Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
B.1.280NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
B.1.1.329NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
ME.1NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
LE.1.3.1NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
XDR.1NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
JN.1.49.1NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
EG.5.1.3NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-18526.8US
HV.1.6NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-18526.8US
XBB.1.16.11NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-18526.8US
FL.15.1.1NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-18526.8US
GK.1.1.1NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
JD.1.1.5NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
B.1NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
B.1.1.441NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
B.1.509NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
B.1.293NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
B.1.1.225NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
B.1.637NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
AY.39 (Delta)NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
AY.26 (Delta)NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
AY.103 (Delta)NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
AY.3 (Delta)NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
JN.1.18.7NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
B.1.396NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
B.1.595.3NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
B.1.2NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
B.1.311NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-17620.4US
B.1.369NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
B.1.367NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
B.1.595NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
B.1.240NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
B.1.1.192NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
JN.1.39.1NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
MB.1NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
LE.1NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
XBB.1.5NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-15598.4US
LF.3NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
MD.1.1NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
LP.3NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
JN.1.5NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
DL.1NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
BA.5.1.15NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
B.1.1.529 (Omicron)NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
BF.41.1NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
BF.39NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
BA.2.3.20NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
AY.33 (Delta)NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
BE.10NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
BA.1.15NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
BA.1.14.2NUS-CDC-N-1GACCCCAAAATCAGCGAAAT20452828728306F-20656.7US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used